Core Insights - Pasithea Therapeutics Corp. has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancers [1][2] Group 1: Clinical Trial Progress - The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with documented RAS, NF1, or RAF mutations, or patients who have failed BRAF/MEK inhibition [3] - The company expects to complete enrollment of all patients in the trial by the end of 2025, having recruited and commenced dosing of the initial three subjects more rapidly than anticipated [2] Group 2: Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, RASopathies, and MAPK pathway driven tumors [4]
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients